Print
|
Close
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Active:
Yes
Cancer Type:
Multiple Myeloma
Plasma cell neoplasm
NCT ID:
NCT03989414
Trial Phases:
Phase I
Phase II
Protocol IDs:
CC-92480-MM-002 (primary)
NCI-2019-04130
2018-004767-31
U1111-1233-5619
Eligibility:
18 Years and older, Male and Female
Study Type:
Treatment
Study Sponsor:
Celgene
NCI Full Details:
http://clinicaltrials.gov/show/NCT03989414
Summary
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in
combination with standard treatments.
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials
.